000154517 001__ 154517
000154517 005__ 20210129213917.0
000154517 0247_ $$2doi$$a10.1038/npp.2014.150
000154517 0247_ $$2ISSN$$a1740-634X
000154517 0247_ $$2ISSN$$a0893-133X
000154517 0247_ $$2ISSN$$a1470-634X
000154517 0247_ $$2WOS$$aWOS:000344834600007
000154517 0247_ $$2altmetric$$aaltmetric:2717139
000154517 0247_ $$2pmid$$apmid:24943643
000154517 037__ $$aFZJ-2014-03831
000154517 082__ $$a610
000154517 1001_ $$0P:(DE-HGF)0$$aHohoff, Christa$$b0$$eCorresponding Author
000154517 245__ $$aAssociation of Adenosine Receptor Gene Polymorphisms and In Vivo Adenosine A1 Receptor Binding in The Human Brain
000154517 260__ $$aLondon$$bNature Publ. Group$$c2014
000154517 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1422266298_24683
000154517 3367_ $$2DataCite$$aOutput Types/Journal article
000154517 3367_ $$00$$2EndNote$$aJournal Article
000154517 3367_ $$2BibTeX$$aARTICLE
000154517 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000154517 3367_ $$2DRIVER$$aarticle
000154517 520__ $$aAdenosine A1 receptors (A1ARs) and the interacting adenosine A2A receptors are implicated in neurological and psychiatric disorders. Variants within the corresponding genes ADORA1 and ADORA2A were shown associated with pathophysiologic alterations, particularly increased anxiety. It is unknown so far, if these variants might modulate the A1AR distribution and availability in different brain regions. In this pilot study, the influence of ADORA1 and ADORA2A variants on in vivo A1AR binding was assessed with the A1AR-selective positron emission tomography (PET) radioligand [18F]CPFPX in brains of healthy humans. Twenty-eight normal control subjects underwent PET procedures to calculate the binding potential BPND of [18F]CPFPX in cerebral regions and to assess ADORA1 and ADORA2A single nucleotide polymorphism (SNP) effects on regional BPND data. Our results revealed SNPs of both genes associated with [18F]CPFPX binding to the A1AR. The strongest effects that withstood even Bonferroni correction of multiple SNP testing were found in non-smoking subjects (N=22) for ADORA2A SNPs rs2236624 and rs5751876 (corr. Pall<0.05). SNP alleles previously identified at risk for increased anxiety like the rs5751876 T-allele corresponded to consistently higher A1AR availability in all brain regions. Our data indicate for the first time that variation of A1AR availability was associated with ADORA SNPs. The finding of increased A1AR availability in regions of the fear network, particularly in ADORA2A risk allele carriers, strongly warrants evaluation and replication in further studies including individuals with increased anxiety.Neuropsychopharmacology advance online publication
000154517 536__ $$0G:(DE-HGF)POF2-333$$a333 - Pathophysiological Mechanisms of Neurological and Psychiatric Diseases (POF2-333)$$cPOF2-333$$fPOF II$$x0
000154517 536__ $$0G:(DE-HGF)POF2-89571$$a89571 - Connectivity and Activity (POF2-89571)$$cPOF2-89571$$fPOF II T$$x1
000154517 588__ $$aDataset connected to CrossRef, juser.fz-juelich.de
000154517 7001_ $$0P:(DE-HGF)0$$aGaribotto, Valentina$$b1
000154517 7001_ $$0P:(DE-Juel1)131679$$aElmenhorst, David$$b2$$ufzj
000154517 7001_ $$0P:(DE-HGF)0$$aBaffa, Anna$$b3
000154517 7001_ $$0P:(DE-Juel1)131691$$aKroll, Tina$$b4$$ufzj
000154517 7001_ $$0P:(DE-HGF)0$$aHoffmann, Alana$$b5
000154517 7001_ $$0P:(DE-HGF)0$$aSchwarte, Kathrin$$b6
000154517 7001_ $$0P:(DE-HGF)0$$aZhang, Weiqi$$b7
000154517 7001_ $$0P:(DE-HGF)0$$aArolt, Volker$$b8
000154517 7001_ $$0P:(DE-HGF)0$$aDeckert, Jürgen$$b9
000154517 7001_ $$0P:(DE-Juel1)131672$$aBauer, Andreas$$b10$$ufzj
000154517 773__ $$0PERI:(DE-600)2008300-2$$a10.1038/npp.2014.150$$p2989–2999$$tNeuropsychopharmacology$$v39$$x1740-634X$$y2014
000154517 8564_ $$uhttp://www.nature.com/npp/journal/vaop/ncurrent/full/npp2014150a.html
000154517 8564_ $$uhttps://juser.fz-juelich.de/record/154517/files/FZJ-2014-03831.pdf$$yRestricted
000154517 909CO $$ooai:juser.fz-juelich.de:154517$$pVDB
000154517 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131679$$aForschungszentrum Jülich GmbH$$b2$$kFZJ
000154517 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131691$$aForschungszentrum Jülich GmbH$$b4$$kFZJ
000154517 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131672$$aForschungszentrum Jülich GmbH$$b10$$kFZJ
000154517 9132_ $$0G:(DE-HGF)POF3-571$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vConnectivity and Activity$$x0
000154517 9131_ $$0G:(DE-HGF)POF2-333$$1G:(DE-HGF)POF2-330$$2G:(DE-HGF)POF2-300$$3G:(DE-HGF)POF2$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lFunktion und Dysfunktion des Nervensystems$$vPathophysiological Mechanisms of Neurological and Psychiatric Diseases$$x0
000154517 9131_ $$0G:(DE-HGF)POF2-89571$$1G:(DE-HGF)POF3-890$$2G:(DE-HGF)POF3-800$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vConnectivity and Activity$$x1
000154517 9141_ $$y2014
000154517 915__ $$0StatID:(DE-HGF)0010$$2StatID$$aJCR/ISI refereed
000154517 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR
000154517 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000154517 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000154517 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000154517 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000154517 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000154517 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000154517 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000154517 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000154517 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000154517 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x0
000154517 980__ $$ajournal
000154517 980__ $$aVDB
000154517 980__ $$aI:(DE-Juel1)INM-2-20090406
000154517 980__ $$aUNRESTRICTED